Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies

JAMA Oncol. 2020 Feb 1;6(2):298-299. doi: 10.1001/jamaoncol.2019.5148.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • B7-H1 Antigen
  • Biomarkers
  • Humans
  • Immunotherapy
  • Lung Neoplasms*
  • Programmed Cell Death 1 Receptor*

Substances

  • B7-H1 Antigen
  • Biomarkers
  • Programmed Cell Death 1 Receptor